Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose rifampicin for difficult-to-treat drug-susceptible tuberculosis
NL-OMON52031Phase 2Not yet recruiting
- Sponsor
- Vall d'Hebron University Hospital
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in drug-susceptible tuberculosis (DS-TB), pulmonary tuberculosis (TB) and extrapulmonary tuberculosis (EPTB) comparing High-dose rifampicin plus standard tuberculosis regimen with Standard-of-care tuberculosis regimen (2 arms). Primary endpoint: Primary safety endpoint. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
rifampicin
03
Conditions
drug-susceptible tuberculosis (DS-TB)pulmonary tuberculosis (TB)extrapulmonary tuberculosis (EPTB)
Beyond the preview
Go deeper on NL-OMON52031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52031.